Oral solid pharmaceutical composition containing clinofibrate

A composition and drug technology, which is applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc., can solve problems such as Clibite hydrophobicity, and achieve good reproducibility, simple process, and good stability

Inactive Publication Date: 2009-10-07
BEIJING D VENTUREPHARM TECH DEV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention prepares an oral solid pharmaceutical composition of clifibrate, which effectively solves the shortcomings of existing clifibrate preparations, and at the same time solves the problem of clifibrate hydrophobicity in a specific way

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral solid pharmaceutical composition containing clinofibrate
  • Oral solid pharmaceutical composition containing clinofibrate
  • Oral solid pharmaceutical composition containing clinofibrate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1 (the existence form of this embodiment is tablet)

[0016]

[0017] Preparation:

[0018] The starch in the recipe amount is prepared into starch slurry, and sodium lauryl sulfate is added and stirred evenly as a binder. The binder is added into the mixed material, granulated, dried, added with magnesium stearate, and pressed into tablets to obtain the finished product.

Embodiment 2

[0019] Embodiment 2 (the existence form of this embodiment is dispersible tablet)

[0020]

[0021] Preparation:

[0022] Add the prescribed amount of sodium lauryl sulfate into purified water, stir to dissolve, and act as a wetting agent. The binder is added to the mixed material, granulated, dried, added with magnesium stearate and an additional part of the disintegrating agent low-substituted hydroxypropyl cellulose, and compressed into tablets to obtain the finished product.

Embodiment 3

[0023] Embodiment 3 (the existence form of this embodiment is capsule)

[0024]

[0025] Preparation:

[0026] Add the prescribed amount of sodium lauryl sulfate into purified water, stir to dissolve, and act as a wetting agent. The binder is added to the mixed material, granulated, dried, added with micropowdered silica gel, packed into a capsule shell, and obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses an oral solid pharmaceutical composition containing clinofibrate. The grain size of the active component of the oral solid pharmaceutical composition is controlled below 30 mum, and the oral solid pharmaceutical composition includes surface-active agent. The oral solid pharmaceutical composition is high in dissolution rate and good in absorptivity and is used for curing hyperlipemia.

Description

technical field [0001] The invention relates to an oral solid pharmaceutical composition for treating hyperlipidemia, in particular to an oral solid pharmaceutical composition containing Clibite. Background technique [0002] Clibet is a new type of fibric acid lipid-lowering new drug, which is effective for various types of hyperlipidemia, and can reduce plasma total cholesterol, triglyceride, low-density lipoprotein, very low-density lipoprotein and lipoprotein The concentration of protein B can increase the concentration of high-density lipoprotein and apolipoprotein A, which can be used not only as the first-line lipid-lowering drug, but also when other lipid-lowering drugs are not effective. The longer the course of treatment and the higher the original blood lipid level, the better the lipid-lowering effect. This product can still delay the progression of atherosclerotic lesions and reduce the risk factors of coronary heart disease. [0003] WO03080118 discloses a ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/20A61K9/48A61K31/194A61P9/12
Inventor 袁筝
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap